According to another report, a minimum of 100 tumor cells in a single tumor tissue biopsy sample is required to evaluate PD-L1 expression for predicting the response of patients with nonsquamous NSCLC to nivolumab therapy (61). Here, CD274 is linked to non-small cell lung carcinoma.